A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis (Q57666978)

2

0 references

J. L. Abitbol

3

0 references

A. Ludolph

4

0 references

J. S. Mora

5

0 references

W. Robberecht

6

0 references

P. J. Shaw

7

0 references

R. M. Pruss

8

0 references

V. Cuvier

9

0 references

V. Meininger

European Journal of Neurology

10

0 references

publication date

21 January 2014

0 references

published in

0 references

volume

21

0 references

issue

3

0 references

page(s)

529-536

0 references

cites work

Emerging targets and treatments in amyotrophic lateral sclerosis

1 reference

Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis

21 January 2018

1 reference

Apoptosis in amyotrophic lateral sclerosis--what is the evidence?

21 January 2018

1 reference

Specific antinociceptive activity of cholest-4-en-3-one, oxime (TRO19622) in experimental models of painful diabetic and chemotherapy-induced neuropathy

21 January 2018

1 reference

Olesoxime (cholest-4-en-3-one, oxime): analgesic and neuroprotective effects in a rat model of painful peripheral neuropathy produced by the chemotherapeutic agent, paclitaxel

21 January 2018

1 reference

Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel

21 January 2018

1 reference

Review: The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis.

21 January 2018

1 reference

Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells.

21 January 2018

1 reference

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

21 January 2018

1 reference

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

21 January 2018

1 reference

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

21 January 2018

1 reference

How can we improve clinical trials in amyotrophic lateral sclerosis?

21 January 2018

1 reference

ALS drug development: reflections from the past and a way forward

21 January 2018

1 reference

Preclinical and subclinical events in motor neuron disease

21 January 2018

1 reference

A clinical trial of creatine in ALS.

21 January 2018

1 reference

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

Design, power, and interpretation of studies in the standard murine model of ALS

21 January 2018

1 reference

A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS.

21 January 2018

1 reference

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial

21 January 2018

1 reference

The natural history of ALS is changing: improved survival

21 January 2018

1 reference